亲爱的研友该休息了!由于当前在线用户较少,发布求助请尽量完整地填写文献信息,科研通机器人24小时在线,伴您度过漫漫科研夜!身体可是革命的本钱,早点休息,好梦!

Subcutaneous immunoglobulin for maintenance treatment in chronic inflammatory demyelinating polyneuropathy (PATH): a randomised, double-blind, placebo-controlled, phase 3 trial

医学 慢性炎症性脱髓鞘性多发性神经病 安慰剂 多神经根神经病 内科学 临床试验 随机对照试验 意向治疗分析 多发性神经病 抗体 物理疗法 外科 儿科 格林-巴利综合征 免疫学 病理 替代医学
作者
Ivo N. van Schaik,Vera Bril,Nan van Geloven,Hans‐Peter Hartung,Richard A. Lewis,Gen Sobue,John‐Philip Lawo,Michaela Praus,Orell Mielke,Billie L. Durn,David R. Cornblath,Ingemar S. J. Merkies,Arman Sabet,Koshy George,L. Jackson Roberts,Ross Carne,Stefan Blum,Robert D. Henderson,Philip Van Damme,Jelle Demeestere
出处
期刊:Lancet Neurology [Elsevier BV]
卷期号:17 (1): 35-46 被引量:254
标识
DOI:10.1016/s1474-4422(17)30378-2
摘要

Approximately two-thirds of patients with chronic inflammatory demyelinating polyneuropathy (CIDP) need long-term intravenous immunoglobulin. Subcutaneous immunoglobulin (SCIg) is an alternative option for immunoglobulin delivery, but has not previously been investigated in a large trial of CIDP. The PATH study compared relapse rates in patients given SCIg versus placebo.Between March 12, 2012, and Sept 20, 2016, we studied patients from 69 neuromuscular centres in North America, Europe, Israel, Australia, and Japan. Adults with definite or probable CIDP who responded to intravenous immunoglobulin treatment were eligible. We randomly allocated participants to 0·2 g/kg or 0·4 g/kg of a 20% SCIg solution (IgPro20) weekly versus placebo (2% human albumin solution) for maintenance treatment for 24 weeks. We did randomisation in a 1:1:1 ratio with an interactive voice and web response system with a block size of six, stratified by region (Japan or non-Japan). The primary outcome was the proportion of patients with a CIDP relapse or who were withdrawn for any other reason during 24 weeks of treatment. Patients, caregivers, and study personnel, including those assessing outcomes, were masked to treatment assignment. Analyses were done in the intention-to-treat and per-protocol sets. This trial is registered with ClinicalTrials.gov, number NCT01545076.In this randomised, double-blind, placebo-controlled trial, we randomly allocated 172 patients: 57 (33%) to the placebo group, 57 (33%) to the low-dose group, and 58 (34%) to the high-dose group. In the intention-to-treat set, 36 (63% [95% CI 50-74]) patients on placebo, 22 (39% [27-52]) on low-dose SCIg, and 19 (33% [22-46]) on high-dose SCIg had a relapse or were withdrawn from the study for other reasons (p=0·0007). Absolute risk reductions were 25% (95% CI 6-41) for low-dose versus placebo (p=0·007), 30% (12-46) for high-dose versus placebo (p=0·001), and 6% (-11 to 23) for high-dose versus low-dose (p=0·32). Causally related adverse events occurred in 47 (27%) patients (ten [18%] in the placebo group, 17 [30%] in the low-dose group, and 20 [34%] in the high-dose group). Six (3%) patients had 11 serious adverse events: one (2%) patient in the placebo group, three (5%) in the low-dose group, and two (3%) in the high-dose group; only one (an acute allergic skin reaction in the low-dose group) was assessed to be causally related.This study, which is to our knowledge, the largest trial of CIDP to date and the first to study two administrations of immunoglobulins and two doses, showed that both doses of SCIg IgPro20 were efficacious and well tolerated, suggesting that SCIg can be used as a maintenance treatment for CIDP.CSL Behring.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
u615138发布了新的文献求助10
1秒前
u615138发布了新的文献求助10
1秒前
1秒前
2秒前
u834401发布了新的文献求助10
3秒前
4秒前
4秒前
英俊的铭的应助被LJH采纳,获得10
4秒前
6秒前
u834401发布了新的文献求助10
6秒前
u588294发布了新的文献求助10
6秒前
u588294发布了新的文献求助10
6秒前
7秒前
8秒前
u314510发布了新的文献求助10
9秒前
u314510发布了新的文献求助10
9秒前
u216593发布了新的文献求助10
9秒前
u216593发布了新的文献求助10
9秒前
11秒前
12秒前
u245792发布了新的文献求助10
12秒前
u488353发布了新的文献求助10
12秒前
u245792发布了新的文献求助10
12秒前
12秒前
13秒前
13秒前
u360016发布了新的文献求助10
15秒前
u620348发布了新的文献求助10
15秒前
u360016发布了新的文献求助10
15秒前
16秒前
17秒前
18秒前
u266829发布了新的文献求助10
18秒前
u996067发布了新的文献求助10
18秒前
烂漫亦巧完成签到,获得积分10
18秒前
u996067发布了新的文献求助10
18秒前
u266829发布了新的文献求助10
18秒前
19秒前
20秒前
u202114发布了新的文献求助10
20秒前
高分求助中
(应助此贴封号)【重要!!请各用户(尤其是新用户)详细阅读】【科研通的精品贴汇总】 10000
拉伸高分子熔体中缠结行为的模拟和小角中子散射研究 1700
The World Atlas of Wine 9th edition 1000
奈特基础组织学:配套组织病理学(第4版)(Netter's Essential Histology With Correlated Histopathology) 800
八旗制度の研究 600
高分子基功能界面水蒸发材料与应用研究 500
外场增强的水汽发电研究 500
热门求助领域 (近24小时)
化学 材料科学 医学 生物 纳米技术 计算机科学 工程类 有机化学 化学工程 生物化学 物理 复合材料 内科学 催化作用 光电子学 人工智能 细胞生物学 无机化学 物理化学 数学
热门帖子
关注 科研通微信公众号,转发送积分 8185137
求助须知:如何正确求助?哪些是违规求助? 9574052
关于积分的说明 21834040
捐赠科研通 7782575
什么是DOI,文献DOI怎么找? 3434520
关于科研通互助平台的介绍 2558743
邀请新用户注册赠送积分活动 2481206